{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-006421","form_type":"8-K","ticker":"CHRN","cik":"0001549084","company_name":"EKSO BIONICS HOLDINGS, INC.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.568628+00:00","generated_at":"2026-06-05T04:42:48.799765+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ekso Bionics reports record 2023 revenue of $18.3M, up 42% YoY","bullets":["Full-year 2023 revenue $18.3M (FY22: $12.9M); sold 151 EksoHealth units.","Q4 2023 revenue $4.8M (+36% YoY); gross margin 49% vs 47%.","Net loss FY23 $15.2M ($1.10/sh) vs $15.1M ($1.16/sh) in FY22.","Cash at Dec 31, 2023: $8.6M, down from $20.5M; raised $3.9M in Jan 2024 offering.","CMS deferred payment determination for personal exoskeletons (Ekso Indego Personal)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-006421","json":"https://secwatch.observer/filing/0001437749-24-006421.json","markdown":"https://secwatch.observer/filing/0001437749-24-006421.md","text":"https://secwatch.observer/filing/0001437749-24-006421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549084/000143774924006421/0001437749-24-006421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549084/000143774924006421/ekso20240302_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:42:48.799765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1fce19f0484e01913459d74c2b8e96c9c95e522e","claim":"EKSO BIONICS HOLDINGS, INC. reported financial results for three and twelve months ended December 31, 2023.","evidence_excerpt":"On March 4, 2024 Ekso Bionics Holdings, Inc. (the “Company”) reported its financial results for the three and twelve months ended December 31, 2023. The full text of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549084/000143774924006421/0001437749-24-006421-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and twelve months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}